reports
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results...
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 • Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a business update. ...
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directo...
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and su...
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual ...
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8th, 2025, at 10:15 am ET. Company management will also participate in one-on-one meetings during the conference, w...
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listi...
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Steven Basta as President and Chief Executive Officer, the Company’s Board of Directors has approved the grant of inducement awards. The Board of Directors approved the grant to Mr. Basta of a non-qualified stock option t...
Phathom Pharmaceuticals Announces Leadership Succession
Phathom Pharmaceuticals Announces Leadership Succession FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven Basta has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Basta succeeds Terrie Curran, who is stepping down as President and CEO and as a member of the Board of Directors for personal reasons. “We are excited to w...
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceutical...
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan) For the first time, Thompson shares his journey living with gastroesophageal reflux disease (GERD) and experience using VOQUEZNA, as part of the new GERD IS NO JOKE campaignVOQUEZNA is a potassium competitive acid blocker (PCAB), the first and only FDA-approved treatment of its kind for both types of GERD1 FLORHAM PARK, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing an...
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Me...
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, to...
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and ...
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized data expected in H2 2025 Robust balance sheet with cash, cash equivalents, and marketable securities of $440 million as of December 31, 2024 is expected to fund operations into H2 2027 SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precisi...
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Fina...
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3Over 300,000 filled prescriptions for VOQUEZNA products, launch-to-date, approximately a 110% increase since last earnings reportPhase 2 EoE trial for VOQUEZNA nearing initiation, with first patient enrollment planned for Q2 2025Management to host conference call today, March 6, 2025, at 8:30 a.m. ET ...
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Fi...
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 Management to host conference call on Thursday, March 6, 2025, at 8:30 am ET FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 6, 2025, to report its fourth quarter and full year 2024 financial results a...
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Confer...
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will also part...
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID C...
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025, at 10:00 am ET. Company management will also participate in one-on-one meetings during the conference, ...
Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Management will present on Tuesday, January 14, 2025, at 9:45 am Pacific Time and will also participate in one-on-one ...
- Jonathan Moreland
OXY OCCIDENTAL PETROLEUM CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
VRSN VERISIGN INC.
TTSH TILE SHOP HOLDINGS INC.
RMAX RE/MAX HOLDINGS INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
PBF PBF ENERGY INC. CLASS A
NMFC NEW MOUNTAIN FINANCE CORPORATION
MTDR MATADOR RESOURCES COMPANY
MMS MAXIMUS INC.
DLY LYONDELLBASELL INDUSTRIES NV
KVHI KVH INDUSTRIES INC.
HRZN HORIZON TECHNOLOGY FINANCE CORP.
GLP GLOBAL PARTNERS LP
FPI FARMLAND PARTNERS REIT
FISI FINANCIAL INSTITUTIONS INC.
FFIC FLUSHING FINANCIAL CORP.
CNC CENTENE CORPORATION
CULP CULP INC.
FI FRANK'S INTERNATIONAL NV
NSC NORFOLK SOUTHERN CORPORATION
PETS PETMED EXPRESS INC.
PLSE PULSE BIOSCIENCES
SENS SENSEONICS HOLDINGS
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
TDW TIDEWATER INC
DOW DOW INC.
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
BCYC BICYCLE THERAPEUTICS
OXLC OXFORD LANE CAPITAL CORP.
PHAT PHATHOM PHARMACEUTICALS
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
REYN REYNOLDS CONSUMER PRODUCTS INC.
PRLD PRELUDE THERAPEUTICS
DLHC DALEIGH HOLDINGS CORP
MASS 908 DEVICES
CTGO CONTANGO ORE INC.
UAN CVR PARTNERS LP
PFX PHENIXFIN CORP
RMBL RUMBLEON INC
XLO XILIO THERAPEUTICS INC
NVCT NUVECTIS PHARMA INC
BIGZ BLACKROCK INNOVATION AND GROWTH TST
BHRB BURKE & HERBERT BANK & TR/VA
ECBK ECB BANCORP INC.
DINO HF SINCLAIR CORP
TKO TKO GROUP HOLDINGS
GAM INC.
MIO GENERAL DE ALQUILER DE MAQUINARIA
SUNS PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
MDRR SUNRISE REALTY TRUST
SIRI MEDALIST DIVERSIFIED REIT INC.
EVM SIRIUS XM HLDGS INC NEW
TXO EATON VANCE INSD CALIF MUN BD FD
MORNINGSTAR PARTNERS
L.P.
- Jonathan Moreland
MTDR MATADOR RESOURCES COMPANY
DLY LYONDELLBASELL INDUSTRIES NV
GLP GLOBAL PARTNERS LP
FISI FINANCIAL INSTITUTIONS INC.
FFIC FLUSHING FINANCIAL CORP.
NSC NORFOLK SOUTHERN CORPORATION
SENS SENSEONICS HOLDINGS
TDW TIDEWATER INC
DOW DOW INC.
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
PHAT PHATHOM PHARMACEUTICALS
CURI CURIOSITYSTREAM INC (A)
MASS 908 DEVICES
CTGO CONTANGO ORE INC.
RMBL RUMBLEON INC
NVCT NUVECTIS PHARMA INC
HR HEALTHCARE TRUST OF AMERICA INC.
BIGZ BLACKROCK INNOVATION AND GROWTH TST
DINO HF SINCLAIR CORP
BHRB BURKE HERBERT FINANCIAL SERVICES CORP
AVDL AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
MIO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
SPGC SPARTA SURGICAL CORP
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correc...
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets Citizen Petition seeks correction of expiration date for New Chemical Entity (NCE) exclusivity on VOQUEZNA (vonoprazan) tablets Orange Book listingsPhathom believes applicable law mandates a 10-year NCE exclusivity period (from date of first approval of drug containing vonoprazan) benefitting all vonoprazan-based products, with exclusivity until May 3, 2032 FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), ...
Erasca Reports Third Quarter 2024 Business Updates and Financial Resul...
Erasca Reports Third Quarter 2024 Business Updates and Financial Results Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution across potentially best-in-class RAS targeting franchise; planned IND submissions on track Robust balance sheet with cash, cash equivalents, and marketable securities of $463 million as of September 30, 2024, is expected to fund operations into H1 2027 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eras...
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results a...
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, over 120% sequential quarterly increaseOver 143,000 prescriptions filled for VOQUEZNA® (vonoprazan) products, launch to date, a 138% increase since last quarterly reportCommercial access for VOQUEZNA tablets expanded, now covering over 80% of U.S. commercial livesManagement to host conference call today, November 7, 2024, at 8:30 am ET FLORHAM PARK, N.J., Nov. 07, 2024 (GLO...
Erasca to Present at Upcoming Investor Conferences
Erasca to Present at Upcoming Investor Conferences SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings. Guggenheim Securities Healthcare Innovation Conference (November 11 – 13, 2024)Location: InterContinental Hotel, Boston, MAFormat: Fireside Chat Date a...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conference...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November and December: Guggenheim’s Inaugural Healthcare Innovation Conference in Boston, MADate: Tuesday, November 12, 2024Live Webcast: 9:30 am ETManagement to participate in ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.